Definition of stereotactic body radiotherapy: Principles and practice for the treatment of stage I non-small cell lung cancer

Strahlentherapie und Onkologie

Volumn 190, Issue 1, 2014, Pages 26-33

  Guckenberger, M ^a   Andratschke, N ^b   Alheit, H ^c   Holy, R ^d   Moustakis, C ^e   Nestle, U ^f   Sauer, O ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c Distler Radiation Oncology ^*  (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Organs at risk; Patient positioning; Quality assurance; Survival; Toxicity

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL EVALUATION; CLINICAL PRACTICE; COMORBIDITY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGING; IMMOBILIZATION; INTERMETHOD COMPARISON; LOBECTOMY; LUNG NON SMALL CELL CANCER; PATIENT SELECTION; PRESCRIPTION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOFREQUENCY ABLATION; STEREOTACTIC BODY RADIATION THERAPY; SURGICAL RISK; TREATMENT PLANNING;

CARCINOMA, NON-SMALL-CELL LUNG; GERMANY; HUMANS; LUNG NEOPLASMS; RADIATION ONCOLOGY; RADIOSURGERY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84891499956     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-013-0450-y     Document Type: Article

References (78)

1. Lax I, Blomgren H, Naslund I, Svanstrom R (1994) Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 33:677-683
2. Uematsu M, Shioda A, Tahara K et al (1998) Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer 82:1062-1070
3. Wulf J, Hadinger U, Oppitz U et al (2000) Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame. Radiother Oncol 57:225-236
4. Herfarth KK, Debus J, Lohr F et al (2000) Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases. Int J Radiat Oncol Biol Phys 46:329-335
5. Benedict SH, Yenice KM, Followill D et al (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 37:4078-4101
6. Potters L, Kavanagh B, Galvin JM et al (2010) American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 76:326-332
7. Kirkbride P, Cooper T (2011) Stereotactic body radiotherapy. Guidelines for commissioners, providers and clinicians: a national report. Clin Oncol 23:163-164
8. Sahgal A, Roberge D, Schellenberg D et al (2012) The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. Clin Oncol 24(9):629-639
9. Loo BW, Chang JY, Dawson LA et al (2011) Stereotactic ablative radiotherapy: what's in a name? Pract Radiat Oncol 1:38-39
10. Raz DJ, Zell JA, Ou SH et al (2007) Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 132:193-199
11. Haasbeek CJ, Palma D, Visser O et al (2012) Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 23:2743-2747
12. Palma D, Visser O, Lagerwaard FJ et al (2010) Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 28:5153-5159
13. Rowell NP, Williams CJ (2001) Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev 2:CD002935
14. Sibley GS, Jamieson TA, Marks LB et al (1998) Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 40:149-154
15. Martel MK, Ten Haken RK, Hazuka MB et al (1999) Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 24:31-37
16. Willner J, Baier K, Caragiani E et al (2002) Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:382-389
17. Partridge M, Ramos M, Sardaro A, Brada M (2011) Dose escalation for non-small cell lung cancer: analysis and modelling of published literature. Radiother Oncol 99:6-11
18. Ginsberg RJ, Rubinstein LV (1995) Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60:615-622 (discussion 622-613)
19. Shirvani SM, Jiang J, Chang JY et al (2012) Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 84:1060-1070
20. Palma D, Lagerwaard F, Rodrigues G et al (2011) Curative treatment of stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. Int J Radiat Oncol Biol Phys (Epub)
21. Guckenberger M, Kestin LL, Hope AJ et al (2012) Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer? J Thorac Oncol 7:542-551
22. Nagata Y, Takayama K, Matsuo Y et al (2005) Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 63:1427-1431
23. Baumann P, Nyman J, Hoyer M et al (2009) Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27:3290-3296
24. Fakiris AJ, McGarry RC, Yiannoutsos CT et al (2009) Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75:677-682
25. Ricardi U, Filippi AR, Guarneri A et al (2010) Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 68:72-77
26. Timmerman R, Paulus R, Galvin J et al (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070-1076
27. Bral S, Gevaert T, Linthout N et al (2011) Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. Int J Radiat Oncol Biol Phys 80:1343-1349
28. Grutters JP, Kessels AG, Pijls-Johannesma M et al (2010) Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 95:32-40
29. Kopek N, Paludan M, Petersen J et al (2009) Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. Radiother Oncol 93:402-407
30. NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer Version 1.2013 [http://www.nccn.org/]
31. Renaud S, Falcoz PE, Olland A, Massard G (2013) Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery? Interact Cardiovasc Thorac Surg 16:68-73
32. Crabtree T, Puri V, Timmerman R et al (2013) Treatment of stage I lung cancer in high-risk and inoperable patients: comparison of prospective clinical trials using stereotactic body radiotherapy (RTOG 0236), sublobar resection (ACOSOG Z4032), and radiofrequency ablation (ACOSOG Z4033). J Thorac Cardiovasc Surg 145:692-699
33. Grills IS, Mangona VS, Welsh R et al (2010) Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 28:928-935
34. Oshiro Y, Aruga T, Tsuboi K et al (2010) Stereotactic body radiotherapy for lung tumors at the pulmonary hilum. Strahlenther Onkol 186:274-279
35. Lagerwaard FJ, Verstegen NE, Haasbeek CJ et al (2012) Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 83:348-353
36. Senan S, Verstegen NE, Palma D et al (2012) Stages I-II non-small cell lung cancer treated using either lobectomy by video-assisted thoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): outcomes of a propensity score-matched analysis. ASCO Meeting Abstracts 30(15-suppl):7009
37. Shelkey J, Fakiris A, DeCamp MM et al (2012) Matched-pair comparison of outcome of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. ASCO Meeting Abstracts 30(15-suppl):7040
38. Bolliger CT, Wyser C, Roser H et al (1995) Lung scanning and exercise testing for the prediction of postoperative performance in lung resection candidates at increased risk for complications. Chest 108:341-348
39. Perrot M de, Licker M, Reymond MA et al (1999) Influence of age on operative mortality and long-term survival after lung resection for bronchogenic carcinoma. Eur Respir J 14:419-422
40. Swensen SJ, Silverstein MD, Ilstrup DM et al (1997) The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med 157:849-855
41. Herder GJ, Kramer H, Hoekstra OS et al (2006) Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 24:1800-1806
42. Patel VK, Naik SK, Naidich DP et al (2013) A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: part 2: pretest probability and algorithm. Chest 143:840-846
43. Patel VK, Naik SK, Naidich DP et al (2013) A practical algorithmic approach to the diagnosis and management of solitary pulmonary nodules: part 1: radiologic characteristics and imaging modalities. Chest 143:825-839
44. Verstegen NE, Lagerwaard FJ, Haasbeek CJ et al (2011) Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol 101:250-254
45. Sawada S, Yamashita MK, Eisaku N et al (2007) Evaluation of resected tumors that were not diagnosed histologically but were suspected of lung cancer preoperatively. J Thorac Oncol 2:S422-S422
46. Murai T, Shibamoto Y, Baba F et al (2010) Progression of non-small-cell lung cancer during the interval before stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 82:463-467
47. De Ruysscher D, Faivre-Finn C, Nestle U et al (2010) European organisation for research and treatment of cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 28:5301-5310
48. Stiles BM, Servais EL, Lee PC et al (2009) Point: clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg 137:13-19
49. Park HK, Jeon K, Koh WJ et al (2010) Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT. Respirology 15:1179-1184
50. Wolthaus JW, Sonke JJ, Herk M van et al (2008) Comparison of different strategies to use four-dimensional computed tomography in treatment planning for lung cancer patients. Int J Radiat Oncol Biol Phys 70:1229-1238
51. Guckenberger M, Krieger T, Richter A et al (2009) Potential of image-guidance, gating and real-time tracking to improve accuracy in pulmonary stereotactic body radiotherapy. Radiother Oncol 91:288-295
52. Paddick I (2000) A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg 93(Suppl 3):219-222
53. Lagerwaard FJ, Haasbeek CJ, Smit EF et al (2008) Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70:685-692
54. Onishi H, Araki T, Shirato H et al (2004) Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101:1623-1631
55. Wulf J, Baier K, Mueller G, Flentje MP (2005) Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 77:83-87
56. Guckenberger M, Wulf J, Mueller G et al (2009) Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74:47-54
57. Grills IS, Hope AJ, Guckenberger M et al (2012) A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol 7:1382-1393
58. Onimaru R, Fujino M, Yamazaki K et al (2008) Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol Biol Phys 70:374-381
59. Zhang J, Yang F, Li B et al (2011) Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 81:e305-e316
60. Guckenberger M, Allgauer M, Appold S. Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S et al (2013) Safety and efficacy of stereotactic body radiotherapy for stage I non-small-cell lung cancer in routine clinical practice. Patterns-of-care and outcome analysis. J Thorac Oncol 8:1050-1058
61. Haedinger U, Krieger T, Flentje M, Wulf J (2005) Influence of calculation model on dose distribution in stereotactic radiotherapy for pulmonary targets. Int J Radiat Oncol Biol Phys 61:239-249
62. Senthi S, Haasbeek CJ, Slotman BJ, Senan S (2013) Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. Radiother Oncol 106:276-282
63. Timmerman R, McGarry R, Yiannoutsos C et al (2006) Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 24:4833-4839
64. Hurkmans CW, Cuijpers JP, Lagerwaard FJ et al (2009) Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol 4:1
65. Wulf J, Hadinger U, Oppitz U et al (2003) Impact of target reproducibility on tumor dose in stereotactic radiotherapy of targets in the lung and liver. Radiother Oncol 66:141-150
66. Guckenberger M, Meyer J, Wilbert J et al (2006) Cone-beam CT based image-guidance for extracranial stereotactic radiotherapy of intrapulmonary tumors. Acta Oncol 45:897-906
67. Guckenberger M, Heilman K, Wulf J et al (2007) Pulmonary injury and tumor response after stereotactic body radiotherapy (SBRT): results of a serial follow-up CT study. Radiother Oncol 85:435-442
68. Takeda T, Takeda A, Kunieda E et al (2004) Radiation injury after hypofractionated stereotactic radiotherapy for peripheral small lung tumors: serial changes on CT. AJR Am J Roentgenol 182:1123-1128
69. Kimura T, Matsuura K, Murakami Y et al (2006) CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers? Int J Radiat Oncol Biol Phys 66:483-491
70. Dunlap NE, Yang W, McIntosh A et al (2012) Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84:1071-1077
71. Huang K, Dahele M, Senan S et al (2012) Radiographic changes after lung stereotactic ablative radiotherapy (SABR)-can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol 102:335-342
72. Fuks Z, Kolesnick R (2005) Engaging the vascular component of the tumor response. Cancer cell 8:89-91
73. Lee Y, Auh SL, Wang Y et al (2009) Therapeutic effects of ablative radiation on local tumor require CD8+T cells: changing strategies for cancer treatment. Blood 114:589-595
74. Kirkpatrick JP, Meyer JJ, Marks LB (2008) The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 18:240-243
75. Brenner DJ (2008) The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol 18:234-239
76. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S (2011) Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 6:2036-2043.
77. Dunlap NE, Cai J, Biedermann GB et al (2010) Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 76:796-801
78. Stephans KL, Djemil T, Tendulkar RD et al (2012) Prediction of chest wall toxicity from lung stereotactic body radiotherapy (SBRT). Int J Radiat Oncol Biol Phys 82:974-980